脑出血患者血浆溶血磷脂类分子含量变化及法舒地尔的影响.docVIP

精品论文 参考文献 脑出血患者血浆溶血磷脂类分子含量变化及法舒地尔的影响 滕玉峰1 张晓霞1 李振光2 于占彩2 (1山东省荣成市石岛管理区港湾卫生院 264309;2潍坊医学院附属文登中心医院 261000) 【中图分类号】R743.34【文献标识码】A【文章编号】1672-5085（2012）14-0012-03 【摘要】目的 观察脑出血患者血浆溶血磷脂类分子（LPA/AP）含量变化的特点及Rho激酶抑制剂的影响，探索脑出血后的病理生理学机制及有效的干预方法。方法 选取脑出血患者128例，测定其血浆溶血磷脂酸（LPA）及其相似磷脂（AP）的含量变化，并与159例脑梗死患者进行比较，年龄匹配的123例健康体检者作为对照组。同时观察Rho激酶抑制剂法舒地尔对脑出血患者血浆LPA、AP含量及预后的影响。 结果 发病24小时脑梗死组血浆LPA的含量（4.22plusmn;0.62mu;mol/l）显著高于脑出血组（2.68plusmn;0.45mu;mol/l）及对照组[（2.57plusmn;0.37mu;mol/l），Plt;0.01]。脑出血组血浆AP含量（6.65plusmn;0.75U）显著高于脑梗死组[（5.39plusmn;0.58U），Plt;0.01]及对照组[（4.09plusmn;0.48mu;mol/l），Plt;0.001]。发病1周，脑出血组血浆AP含量仍高于脑梗死组和对照组（Plt;0.01）。发病72小时应用Rho激酶抑制剂法舒地尔能够显著降低脑出血患者血浆AP含量，改善病人预后。结论 脑出血患者血浆AP含量显著升高，提示脑出血后2周内均存在缺血性膜损伤；Rho激酶抑制剂法舒地尔能有效降低血浆AP含量，改善患者预后，具有神经保护作用。 【关键词】脑出血 溶血磷脂类分子 缺血性膜损伤 法舒地尔 A Clinical Study of Plasma Lysophospholipids Levels in Patients with Intracerebral Hemorrhage and Effects of Fasudil TENG Yu-feng1, LI Zhen-guang2, YU Zhan-cai2. 1 Rongcheng Shidao Harbour Hospital, Shandong Province, 264309, China 2 Department of Neurology, Wendeng Central Hospital, Shandong Province, 264400, China 【Abstract】 Objectives To investigate the changes of plasma lysophosphatidic acid (LPA) or acidic phospholipids (AP) levels in patients with intracerebral hemorrhage (ICH) . Meanwhile, effects of the Rho-kinase inhibitor, fasudil, on LPA/AP levels and patientsrsquo; outcome were observed. Methods The present study examined plasma LPA/AP levels using fresh fetched blood in 128 cases of ICH, 123 controls and 159 cases of ischemic stroke enrolled in the LPA and Stroke Prevention Study. LPA was assayed by measuring its inorganic phosphorus after separation by chromatograph. Meanwhile, the effects of the Rho-kinase inhibitor, fasudil, on plasma LPA/AP levels and patientrsquo;s prognosis were observed. Results Within 24 hours after onset, an elevated LPA levels were seen in cases (n=159) with ischemic stroke (4.22plusmn;0.62mu;mol/l ) comparing with 123 controls (2.57plusmn;0.37mu;mol